Skip to main content

Advertisement

Table 7 Adverse events in patients treated as second-or-greater line setting (n = 102)

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Adverse event G0 G1 G2 G3 G4 NE All grades (%) Grade 3/4 (%)
Leucocyte 6 5 13 34 42 2 92.2 74.5
Neutrophils 7 4 12 22 54 3 90.2 74.5
Hemoglobin 17 33 30 18 2 2 81.4 19.6
Platelets 36 18 12 21 13 2 62.7 33.3
AST 65 32 1 2 0 2 34.3 2.0
ALT 60 30 8 2 0 2 39.2 2.0
Anorexia 39 45 10 2 0 6 55.9 2.0
Nausea 48 38 10 1 0 5 48.0 1.0
Vomiting 77 17 3 0 0 5 19.6 0.0
Diarrhea 86 9 1 1 0 5 10.8 1.0
Fatigue 36 47 10 5 0 4 60.8 4.9
Febrile neutropenia 91 0 0 10 0 1 9.8 9.8
Fever 73 16 11 0 0 2 26.5 0.0
Infection 89 4 4 3 1 1 11.8 3.9
Dyspnea 93 4 1 3 0 1 7.8 2.9
Interstitial pneumonia 94 2 1 4 0 1 6.9 3.9
Neuropathy 96 0 5 0 0 1 4.9 0.0
Rash 90 2 5 4 0 1 10.8 3.9
Edema 101 0 1 0 0 0 1.0 0.0
Mucositis 99 1 2 0 0 0 2.9 0.0
Allergic reaction 100 0 2 0 0 0 2.0 0.0
  1. AST aspartate transaminase, ALT alanine aminotransferase